Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 8
Results: 7
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.
- Published in:
- CNS Drugs, 2022, v. 36, n. 8, p. 803, doi. 10.1007/s40263-022-00939-9
- By:
- Publication type:
- Article
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
- Published in:
- CNS Drugs, 2022, v. 36, n. 8, p. 897, doi. 10.1007/s40263-022-00938-w
- By:
- Publication type:
- Article
Antiseizure Drugs and Movement Disorders.
- Published in:
- CNS Drugs, 2022, v. 36, n. 8, p. 859, doi. 10.1007/s40263-022-00937-x
- By:
- Publication type:
- Article
The Options for Neuraxial Drug Administration.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.
- Published in:
- 2022
- By:
- Publication type:
- journal article